Should I buy or sell DBV Technologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares. View DBVT analyst ratings or view top-rated stocks .

What is DBV Technologies' stock price target for 2024?

3 brokers have issued twelve-month target prices for DBV Technologies' stock. Their DBVT share price targets range from $1.00 to $10.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 624.5% from the stock's current price. View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts .

How have DBVT shares performed in 2024?

DBV Technologies' stock was trading at $0.9528 at the beginning of the year. Since then, DBVT stock has decreased by 27.6% and is now trading at $0.6901. View the best growth stocks for 2024 here .

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our DBVT earnings forecast .

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.10. The firm earned $8.88 million during the quarter, compared to analysts' expectations of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative trailing twelve-month return on equity of 46.33%. During the same quarter in the prior year, the business posted ($0.23) EPS.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT) , OPKO Health (OPK) , Bellicum Pharmaceuticals (BLCM) , Axsome Therapeutics (AXSM) , Gilead Sciences (GILD) , Novavax (NVAX) , AbbVie (ABBV) , Pieris Pharmaceuticals (PIRS) , Pfizer (PFE) and Sangamo Therapeutics (SGMO) .

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DBVT

DBV Technologies (DBVT) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free DBVT Stock Alerts

$0.69

+0.01 (+1.47%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.66
▼
$0.72
50-Day Range: $0.68
▼
$0.90
52-Week Range: $0.65
▼
$2.37

Volume: 19,220 shs
Average Volume: 50,278 shs
Market Capitalization: $133.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get DBV Technologies alerts:

DBV Technologies MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 624.5% Upside
$5.00 Price Target
Short Interest: Bearish
0.28% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1,624 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.88) to ($0.14) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

Medical Sector

664th out of 918 stocks

Biological Products, Except Diagnostic Industry

110th out of 150 stocks

3.2

Analyst's Opinion

Consensus Rating
DBV Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
DBV Technologies has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.28% of the outstanding shares of DBV Technologies have been sold short.
Short Interest Ratio / Days to Cover
DBV Technologies has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
Change versus previous month
Short interest in DBV Technologies has recently increased by 0.05%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
DBV Technologies does not currently pay a dividend.
Dividend Growth
DBV Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DBVT.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 1 article on an average week.
Search Interest
1 people have searched for DBVT on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DBV Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,624.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.71% of the stock of DBV Technologies is held by insiders.
Percentage Held by Institutions
71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for DBV Technologies are expected to grow in the coming year, from ($0.88) to ($0.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DBV Technologies is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DBV Technologies is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DBV Technologies has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About DBV Technologies Stock (NASDAQ:DBVT)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DBVT Stock News Headlines

April 18, 2024 | americanbankingnews.com

Vigil Neuroscience (NASDAQ:VIGL) and DBV Technologies (NASDAQ:DBVT) Head-To-Head Review

April 12, 2024 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 4, 2024 | finance.yahoo.com

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

March 20, 2024 | seekingalpha.com

DBVT DBV Technologies S.A.

March 15, 2024 | wsj.com

DBV Technologies S.A. ADR

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes

March 8, 2024 | finance.yahoo.com

DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 8, 2024 | finanznachrichten.de

DBV Technologies S.A.: DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

March 8, 2024 | globenewswire.com

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

March 7, 2024 | finance.yahoo.com

DBV Technologies SA Reports Decrease in Net Loss and Advances Clinical Programs in Full Year ...

March 7, 2024 | msn.com

DBVT Stock Earnings: DBV Technologies Beats EPS, Beats Revenue for Q4 2023

March 7, 2024 | globenewswire.com

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

March 4, 2024 | globenewswire.com

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

February 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials

February 24, 2024 | msn.com

DBV Technologies S.A. - Depositary Receipt () (DBVT) Price Target Increased by 15.78% to 2.62

February 20, 2024 | finanznachrichten.de

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

February 20, 2024 | finance.yahoo.com

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

February 20, 2024 | globenewswire.com

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

February 13, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

February 9, 2024 | msn.com

DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying

January 22, 2024 | finance.yahoo.com

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 9, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

January 4, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

December 4, 2023 | finance.yahoo.com

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023

November 27, 2023 | msn.com

Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

See More Headlines

Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:DBVT
CUSIP: N/A
CIK: 1613780
Web: www.dbv-technologies.com
Phone: (315) 542-7878
Fax: 33-1-43-26-10-83
Employees: 104
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $10.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +624.5%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,730,000.00
Net Margins: -461.32%
Pretax Margin: -462.35%
Return on Equity: -46.33%
Return on Assets: -35.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.26
Quick Ratio: 4.26

Sales & Book Value

Annual Sales: $15.73 million
Price / Sales: 8.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.73 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 192,870,000
Free Float: 191,500,000
Market Cap: $133.10 million
Optionable: Optionable
Beta: 0.75

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Daniel Tassé (Age 64)
CEO & Director
Comp: $1.21M
Dr. Pharis Mohideen (Age 59)
Chief Medical Officer
Comp: $725.12k
Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)
CFO & Principal Accounting Officer
Dr. Kevin P. Malobisky M.S.
Ph.D., R.A.C., Chief Operations Officer
Ms. Michele F. Robertson
Chief Legal Officer
Ms. Caroline Daniere (Age 49)
Chief Human Resources Officer & Chief of Staff
Dr. Wence Agbotounou
Chief Clinical Trial Officer & Senior VP
Mr. Edward P. Jordan M.B.A. (Age 56)
Senior Vice President of Commercial Operations North America
Alan Kerr
Senior VP & Head of Global Regulatory Affairs
Mr. Pascal Wotling
Chief External Manufacturing & Supply Chain Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DBVT Stock Analysis - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares.
View DBVT analyst ratings or view top-rated stocks.
What is DBV Technologies' stock price target for 2024?: 3 brokers have issued twelve-month target prices for DBV Technologies' stock. Their DBVT share price targets range from $1.00 to $10.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 624.5% from the stock's current price.
View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts.
How have DBVT shares performed in 2024?: DBV Technologies' stock was trading at $0.9528 at the beginning of the year. Since then, DBVT stock has decreased by 27.6% and is now trading at $0.6901.
View the best growth stocks for 2024 here.
When is DBV Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our DBVT earnings forecast.

How were DBV Technologies' earnings last quarter?: DBV Technologies S.A. (NASDAQ:DBVT) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.10. The firm earned $8.88 million during the quarter, compared to analysts' expectations of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative trailing twelve-month return on equity of 46.33%. During the same quarter in the prior year, the business posted ($0.23) EPS.
What other stocks do shareholders of DBV Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).
How do I buy shares of DBV Technologies?: Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DBVT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial